BrainsWay Ltd. American Depositary Shares (BWAY)
FairStock Score: 45/100 — MIXED
Key Financials
| Current Price | $11.25 |
| Market Cap | $642M |
| P/E Ratio | 48.91 |
| ROE | 12.82% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At $11.92 on 2026-10-13, BrainsWay has a $641.7 million market capitalization. In fiscal Q2 2026, the latest quarter, revenue was $17.1 million and net income was $2.7 million, a 15.84% net margin. The supplied growth metrics are strong—both revenue and profit growth are above 30%—though the period for those rates is not specified in the data. That is a promising growth profile, and the balance sheet is conservative: D/E is 0.09, Altman Z-Score is 8.80, and Piotroski F-Score is 6/9. Trailing free cash flow is $5.7 million, while ROE is 12.82% and ROCE is 4.05%. The modest ROCE means the data do not yet demonstrate a wide moat. FairStock's Lynch category is none because there are only 0 years of filed results, needing 3. Valuation is the main hurdle. FairStock's calculations from the 2026-10-13 close show a P/E of 51.83, P/B of 5.84, EV/EBITDA of 43.33, and FCF yield of 0.9%. The Graham Number is $3.19, so the price carries a margin of safety of -273.67%; there is no Graham-style cushion. Beta is 0.08, but low price volatility does not make an expensive asset safe. I prefer businesses that combine durable returns on capital with a fair price. BrainsWay is growing, profitable, and lightly indebted, but it is small and priced for much larger future profits. I would want either a lower price or stronger returns on capital and cash generation before calling it a compelling value.
In plain English: BrainsWay makes noninvasive brain stimulation treatments for mental health and other conditions. The business is growing and profitable with little debt, but it is still small and the stock price looks rich compared with its profits, accounting value, and cash flow. In plain terms, the company looks financially healthy but expensive relative to what it currently earns.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer